Voronoi Submits Clinical Trial Plan Amendment for VRN110755 to EMA, Expanding Global Phase 1/2 Study in EGFR Mutant NSCLC
Voronoi announced that it has completed submission of a clinical trial plan amendment for VRN110755 in EGFR mutant non-small cell lung cancer to the European Medicines Agency EMA.
This submission adds Europe to previously approved regions including Taiwan, Australia, and Singapore, expanding the global scope of the Phase 1/2 study.
Based on safety and early efficacy signals from Phase 1a, the trial expands to Phase 1b/2 with approximately 391 patients.
This disclosure has no direct capital or financial impact, and no treasury stock transactions or dividends were mentioned.
[AI Summary]Voronoi's EMA submission for VRN110755 global trial expansion is a routine clinical development step with no capital structure or financial effects. Success could boost stock price, but high uncertainty at this stage requires careful risk assessment.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)